Literature DB >> 17465442

Relationship of functional gastrointestinal disorders and psychiatric disorders: implications for treatment.

Carol S North, Barry A Hong, David H Alpers.   

Abstract

This article revisits the links between psychopathology and functional gastrointestinal disorders such as irritable bowel syndrome (IBS), discusses the rational use of antidepressants as well as non-pharmacological approaches to the management of IBS, and suggests guidelines for the treatment of IBS based on an interdisciplinary perspective from the present state of knowledge. Relevant published literature on psychiatric disorders, especially somatization disorder, in the context of IBS, and literature providing direction for management is reviewed, and new directions are provided from findings in the literature. IBS is a heterogeneous syndrome with various potential mechanisms responsible for its clinical presentations. IBS is typically complicated with psychiatric issues, unexplained symptoms, and functional syndromes in other organ systems. Most IBS patients have multiple complaints without demonstrated cause, and that these symptoms can involve systems other than the intestine, e.g. bones and joints (fibromyalgia, temporomandibular joint syndrome), heart (non-cardiac chest pain), vascular (post-menopausal syndrome), and brain (anxiety, depression). Most IBS patients do not have psychiatric illness per se, but a range of psychoform (psychological complaints in the absence of psychiatric disorder) symptoms that accompany their somatoform (physical symptoms in the absence of medical disorder) complaints. It is not correct to label IBS patients as psychiatric patients (except those more difficult patients with true somatization disorder). One mode of treatment is unlikely to be universally effective or to resolve most symptoms. The techniques of psychotherapy or cognitive-behavioral therapy can allow IBS patients to cope more readily with their illness. Specific episodes of depressive or anxiety disorders can be managed as appropriate for those conditions. Medications designed to improve anxiety or depression are not uniformly useful for psychiatric complaints in IBS, because the psychoform symptoms that sound similar to those seen in psychiatric disorders may not have the same significance in patients with IBS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17465442      PMCID: PMC4319119          DOI: 10.3748/wjg.v13.i14.2020

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  49 in total

1.  The validity and significance of the clinical diagnosis of hysteria (Briquet's syndrome).

Authors:  S B Guze
Journal:  Am J Psychiatry       Date:  1975-02       Impact factor: 18.112

Review 2.  Use of psychopharmacological agents for functional gastrointestinal disorders.

Authors:  R E Clouse; P J Lustman
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

Review 3.  Diet and irritable bowel syndrome.

Authors:  David H Alpers
Journal:  Curr Opin Gastroenterol       Date:  2006-03       Impact factor: 3.287

Review 4.  Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials.

Authors:  R B Lydiard; S A Falsetti
Journal:  Am J Med       Date:  1999-11-08       Impact factor: 4.965

Review 5.  Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials.

Authors:  J Jailwala; T F Imperiale; K Kroenke
Journal:  Ann Intern Med       Date:  2000-07-18       Impact factor: 25.391

Review 6.  Treatments targeting putative mechanisms in irritable bowel syndrome.

Authors:  Filippo Cremonini; Nicholas J Talley
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2005-02

7.  Cognitive-behavioral therapy for somatization disorder: a randomized controlled trial.

Authors:  Lesley A Allen; Robert L Woolfolk; Javier I Escobar; Michael A Gara; Robert M Hamer
Journal:  Arch Intern Med       Date:  2006-07-24

8.  Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial.

Authors:  R E Clouse; P J Lustman; T C Eckert; D M Ferney; L S Griffith
Journal:  Gastroenterology       Date:  1987-04       Impact factor: 22.682

9.  The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome.

Authors:  Francis Creed; Lakshmi Fernandes; Elspeth Guthrie; Stephen Palmer; Joy Ratcliffe; Nicholas Read; Christine Rigby; David Thompson; Barbara Tomenson
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

10.  Psychiatric diagnoses, sexual and physical victimization, and disability in patients with irritable bowel syndrome or inflammatory bowel disease.

Authors:  E A Walker; A N Gelfand; M D Gelfand; W J Katon
Journal:  Psychol Med       Date:  1995-11       Impact factor: 7.723

View more
  46 in total

1.  Sertraline and low-dose doxepin treatment in severe agitated-anxious depression with significant gastrointestinal complaints:two case reports.

Authors:  Lisa Maclean; Brian K Ahmedani
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Dietary aspects in fibromyalgia patients: results of a survey on food awareness, allergies, and nutritional supplementation.

Authors:  Laura-Isabel Arranz; Miguel-Ángel Canela; Magda Rafecas
Journal:  Rheumatol Int       Date:  2011-07-22       Impact factor: 2.631

3.  CNP signal pathway up-regulated in rectum of depressed rats and the interventional effect of Xiaoyaosan.

Authors:  Ping Li; Xu-Dong Tang; Zheng-Xu Cai; Juan-Juan Qiu; Xue-Lian Lin; Tong Zhu; Lawrence Owusu; Hui-Shu Guo
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

Review 4.  Psychologists in Academic Health Centers and Medical Centers: Being Visible, Relevant and Integral.

Authors:  Barry A Hong; William N Robiner
Journal:  J Clin Psychol Med Settings       Date:  2016-03

Review 5.  Vagal sensory neurons and gut-brain signaling.

Authors:  Chuyue D Yu; Qian J Xu; Rui B Chang
Journal:  Curr Opin Neurobiol       Date:  2020-05-04       Impact factor: 6.627

6.  Irritable Bowel Syndrome and Co-morbid Gastrointestinal and Extra-gastrointestinal Functional Syndromes.

Authors:  Ami D Sperber; Roy Dekel
Journal:  J Neurogastroenterol Motil       Date:  2010-04-27       Impact factor: 4.924

7.  Rates and predictors of oral medication adherence in pediatric patients with IBD.

Authors:  Neal S LeLeiko; Debra Lobato; Sarah Hagin; Elizabeth McQuaid; Ronald Seifer; Sheryl J Kopel; Julie Boergers; Jack Nassau; Kristina Suorsa; Jason Shapiro; Barbara Bancroft
Journal:  Inflamm Bowel Dis       Date:  2013 Mar-Apr       Impact factor: 5.325

8.  Urological symptoms in a subset of patients with urological chronic pelvic pain syndrome and a polysymptomatic, polysyndromic pattern of presentation.

Authors:  H Henry Lai; Carol S North; Gerald L Andriole; Lori Cupps; David Song; Timothy J Ness; Barry A Hong
Journal:  J Urol       Date:  2013-12-19       Impact factor: 7.450

Review 9.  A role for corticotropin-releasing factor in functional gastrointestinal disorders.

Authors:  Yvette Taché; Cornelia Kiank; Andreas Stengel
Journal:  Curr Gastroenterol Rep       Date:  2009-08

10.  Contributions of the cerebellum to disturbed central processing of visceral stimuli in irritable bowel syndrome.

Authors:  Christina Rosenberger; Markus Thürling; Michael Forsting; Sigrid Elsenbruch; Dagmar Timmann; Elke R Gizewski
Journal:  Cerebellum       Date:  2013-04       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.